The potential for a placebo effect and the confounding influence of weight loss on PD symptoms also require careful consideration in interpreting results
The rush to capitalise on GLP-1 drugs success is having wider implications for the pharmaceutical industry: Manufacturing capacity is being diverted from other therapeutic areas to meet GLP-1 demand
In patients with HCC complicated by esophageal varices, the efficacy of AR modulators in preventing bleeding should be determined based on tumor staging
expounded on the obesity paradox, suggesting increased BMD is offset by poor bone quality due to advanced glycation end-products (AGEs) accumulation, impaired osteoblast function, and uncoupled bone turnover favoring resorption
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5) Diabetes
REWIND enrolled a notably broad population: only 31% had established cardiovascular disease at baseline, making it the first GLP-1 RA cardiovascular outcomes trial to demonstrate benefit in a primary-prevention-weighted cohort
